SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE CRYPTO community is fiercely active, rallying around its "OG" Rage Guy meme status and the recent restoration of its original meme-making platforms, as dedicated holders express high conviction in its potential for massive growth by consistently building during challenging market conditions.

Memecoin on Injective taken over by the community.

Nonja

NONJA is gaining significant attention as the leading meme on the Injective ($INJ) ecosystem, which its dedicated community views as profoundly undervalued with robust developer activity and potential ETFs. Enthusiasts are highlighting NONJA's "unruggable" structure, strong community, and organic growth as key drivers for potential "asymmetric, explosive returns" as the broader market discovers INJ's fundamental strength.

Cornerstone Total Return Fund, Inc. is an open-end, diverse management organization. Its primary goal is to pursue capital growth, with current income as a secondary goal. The corporation makes investments in a variety of industries, including real estate, utilities, industrials, health care, financial services, telecommunication networks, and information systems.

Cornerstone Total Return Fund

Cornerstone Total Return Fund Inc.

The Cornerstone Total Return Fund ($CRF) is seeing heightened discussion due to recent share price volatility and strong speculation about an upcoming Rights Offering, driven by its premium to Net Asset Value. The community is actively debating the timing and impact of such an offering, while many view current dips as buying opportunities, emphasizing the fund's attractive dividend reinvestment plan and potential for increased distributions.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of BYSANTI for bipolar I disorder and schizophrenia, a new CNS drug with patent protection until 2044. The community is actively discussing its significant undervaluation and potential for a massive rerating or buyout, especially given the long patent runway and the anticipated 'mega blockbuster' potential of its Tradipitant pipeline for GLP-1 induced nausea.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas (GASS) is trending amid high speculative interest, with its community actively discussing and promoting it as the next major meme coin, drawing comparisons to past successes like PEPE and SHIB. Despite strong contrasting opinions labeling it a pump-and-dump, many holders are focused on collective buying and long-term holding to drive its potential valuation.

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

ArriVent BioPharma Inc.

ArriVent BioPharma is trending as the community eagerly anticipates crucial Phase 3 study results for its lung cancer treatment, firmonertinib, driving significant options activity and speculation despite a relatively quiet board. Many are employing options strategies, anticipating volatility and a potential market reaction to the upcoming data readout for its promising pipeline asset.

Polygon

Polygon (POL) is trending due to its strategic pivot into regulated payments and Real-World Assets, driven by recent acquisitions and increasing on-chain usage, particularly from AI-powered transactions. The community is buzzing about its enhanced utility, deflationary tokenomics, and long-term potential to transform financial infrastructure.

Pegasystems, Inc. engages in the development, market, license, and support of software, which allows organizations to build, deploy, and change enterprise applications. Its product, Pega Infinity, helps connect enterprises to their customers in real-time across channels, streamline business operations, and adapt to meet changing requirements. The company was founded by Alan Trefler in 1983 and is headquartered in Waltham, MA.

Pegasystems Inc.

Pegasystems is trending following strong Q4 earnings, optimistic FY26 guidance, and a significant $1B share repurchase increase, which initially saw a "sell the news" reaction. The community is actively discussing PEGA's unique position as an AI beneficiary in enterprise automation, further bolstered by multiple analyst upgrades and a favorable legal development in the Appian lawsuit.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending amidst community excitement over upcoming smart contracts and its high-speed BlockDAG technology, with investors actively discussing its potential as a scalable Proof-of-Work alternative and noting ongoing whale accumulation.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending as its FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor and positive epilepsy trial data drive significant analyst price target increases, while the community actively debates its commercialization prospects against concerns of dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVie (NYSE:ABBV) Upgraded to Strong-Buy at Barclays

Barclays upgraded AbbVie to a "strong-buy" rating in a report on Thursday...

Bristol Myers Squibb (NYSE:BMY) Upgraded to "Strong-Buy" at Barclays

Barclays raised shares of Bristol Myers Squibb to a "strong-buy" rating in a research note on Thursday...

Etsy (NYSE:ETSY) Upgraded to Strong-Buy at Barclays

Barclays upgraded Etsy from a "hold" rating to a "strong-buy" rating in a research note on Thursday...

Barclays Upgrades Pfizer (NYSE:PFE) to "Strong Sell"

Barclays raised shares of Pfizer to a "strong sell" rating in a research report on Thursday...

Gilead Sciences (NASDAQ:GILD) Rating Increased to Hold at Barclays

Barclays upgraded Gilead Sciences to a "hold" rating in a research report on Thursday...

Amgen (NASDAQ:AMGN) Rating Increased to Hold at Barclays

Barclays raised shares of Amgen to a "hold" rating in a research report on Thursday...

Barclays Upgrades Biogen (NASDAQ:BIIB) to Hold

Barclays upgraded shares of Biogen to a "hold" rating in a report on Thursday...

Eli Lilly and Company (NYSE:LLY) Stock Rating Upgraded by Barclays

Barclays upgraded shares of Eli Lilly and Company to a "strong-buy" rating in a report on Thursday...

Barclays Upgrades Merck & Co., Inc. (NYSE:MRK) to Strong-Buy

Barclays upgraded shares of Merck & Co., Inc. to a "strong-buy" rating in a research note on Thursday...

Bloomberg Surveillance 2/20/2026

Jonathan Ferro, Lisa Abramowicz and Annmarie Hordern speak daily with leaders and decision makers from Wall Street to Washington and beyond. No other program better positions investors and executives...

Barclays PLC is a bank holding company, which engages in the provision of retail banking, credit cards, corporate and investment banking, and wealth management services. It operates through the following segments: Barclays United Kingdom (UK), Barclays United Kingdom (UK) Corporate Bank, Barclays Private Bank and Wealth Management, Barclays Investment Bank, Barclays United States (US) Consumer Bank, and Head Office. The Barclays UK segment represents businesses that sit within the UK ring-fenced bank entity, Barclays Bank UK PLC, and comprises personal banking, business banking and Barclaycard consumer UK. The Barclays UK Corporate Bank segment focuses on bringing together lending, trade and working capital, liquidity, payments, and FX solutions for UK corporate clients. The Barclays Private Bank and Wealth Management segment serves UK and international private banking clients. The Barclays Investment Bank segment incorporates the global markets, investment banking, and international corporate banking businesses. The Barclays US Consumer Bank segment relates to co-branded credit card issuer and financial services partner in the United States. The Head Office segment comprises central support, central treasury operations, Barclays Execution Services assets and legacy businesses. The company was founded on 1690 and is headquartered in London, the United Kingdom.

Current Price	$25.99
Prev Close	$25.60
Open	$25.86
Dividend Yield	1.79%
50-Day Moving Average	$25.75
Beta	1.18
Avg. Volume	5.04M
PE Ratio	11.32

52-Week High	$27.70
52-Week Low	$12.14
Market Capitalization	$89.64B
EPS (Annual)	$2.31
Price to Book	1.03
Revenue Per Employee	$773,899.17

BCS
Barclays PLC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCS News

BCSBarclays PLC